Clinical trial
A Study of Specific HCC Antigens CD8+ T Cells Therapy for Treating Patients With Relapsed/Advanced Hepatocellular Carcinoma (HCC)
NCT03175705 is registered in ClinicalTrials.gov with Beijing YouAn Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of Specific HCC Antigens CD8+ T Cells Therapy for Treating Patients With Relapsed/Advanced Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Beijing YouAn Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 1, 2017
- Completion date
- March 30, 2019
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma